Predictive and prognostic clinical and pathological factors of nivolumab efficacy in non-small-cell lung cancer patients


Por: Garde-Noguera J, Martin-Martorell P, De Julian M, Perez-Altozano J, Salvador-Coloma C, Garcia-Sanchez J, Insa-Molla A, Martin M, Mielgo-Rubio X, Marin-Liebana S, Blasco-Cordellat A, Blasco-Molla S, Girones R, Marquez-Medina D, Aparisi F, Cerda M, Macia-Escalante S, Sanchez A, Juan-Vidal O

Publicada: 1 ago 2018
Resumen:
Immunotherapy increases overall response rate (ORR) and overall survival (OS) in patients with non-small-cell lung cancer (NSCLC). Prognostic and predictive factors are a high need. Retrospective review of NSCLC patients treated with nivolumab was performed. Analyzed variables included age, sex, stage, performance status (PS), location of metastases, presence of tumour-related symptoms and comorbidities, number of metastasis locations, previous chemotherapy, anti-angiogenic and radiotherapy treatments, and analytical data from the standard blood count and biochemistry. A total of 175 patients were included. Median age was 61.5 years, 73.1% were men, 77.7% were ECOG-PS 0-1, and 86.7% were included with stage IV disease. Histology was non-squamous in 77.1%. Sixty-five received nivolumab in second line (37.1%). Thirty-eight patients had brain metastasis (22%), and 39 (22.3%) liver metastasis and 126 (72%) had more than one metastatic location. The ORR was 15.7% with median Progression free survival (PFS) 2.8 months and median OS 5.81 months. Stage III vs IV and time since the beginning of the previous line of treatment 6 vs < 6 months were associated with better response. PS 2, time since the previous line of treatment < 6 vs 6 months, and more than one metastatic location were independently associated with shorter OS in multivariable analysis (7.8 vs 2.7 months, 11.2 vs 4.6 months, and 9.4 vs 5.1 month). Finally, time since the previous treatment < 6 vs 6 months and more than one metastatic location were independently associated with shorter PFS in multivariable analysis (4.3 vs 2.3 months and 4.7 vs 2.3 months). Poor PS, short period of time since the previous treatment, and more than one metastatic location were associated with poorer prognostic.

Filiaciones:
Garde-Noguera J:
 Hosp Arnau Vilanova, C St Climent 12, Valencia 46015, Spain

Martin-Martorell P:
 Univ Hosp Clin Valencia, Valencia, Spain

De Julian M:
 Hosp Prov Castellon, Castellon de La Plana, Spain

Perez-Altozano J:
 Hosp Gen Elche, Elche, Spain

Salvador-Coloma C:
 Hosp Univ Politecn La Fe, Valencia, Spain

Garcia-Sanchez J:
 Hosp Arnau Vilanova, C St Climent 12, Valencia 46015, Spain

Insa-Molla A:
 Univ Hosp Clin Valencia, Valencia, Spain

Martin M:
 Hosp Dr Peset, Valencia, Spain

Mielgo-Rubio X:
 Hosp Univ Fdn Alcorcon, Alcorcon, Spain

Marin-Liebana S:
 Hosp Manises, Manises, Spain

Blasco-Cordellat A:
 Hosp Gen Univ Valencia, Valencia, Spain

Blasco-Molla S:
 Hosp Sagunto, Sagunto, Spain

Girones R:
 Hosp Lluis Alcanyis, Xativa, Spain

Marquez-Medina D:
 Hosp Arnau Vilanova, Lleida, Spain

Aparisi F:
 Hosp Virgen Lirios, Alcoy, Spain

Cerda M:
 Univ Politecn Valencia, Valencia, Spain

Macia-Escalante S:
 Pivotal CRO, Madrid, Spain

Sanchez A:
 Hosp Prov Castellon, Castellon de La Plana, Spain

Juan-Vidal O:
 Hosp Univ Politecn La Fe, Valencia, Spain
ISSN: 1699048X





CLINICAL & TRANSLATIONAL ONCOLOGY
Editorial
SPRINGER-VERLAG ITALIA SRL, VIA DECEMBRIO, 28, MILAN, 20137, ITALY, Italia
Tipo de documento: Article
Volumen: 20 Número: 8
Páginas: 1072-1079
WOS Id: 000438705900014
ID de PubMed: 29368144

MÉTRICAS